As the cost of travel has decreased, more and more people are choosing to travel abroad for business and leisure. As a result, they can be exposed to pathogens non-endemic to their countries of origin. Ensuring that patients are vaccinated to reduce the risk of infection while travelling is an important tenet of practicing travel medicine.
Insurers in the US offer significantly variable coverage of travel vaccines, and this will often affect which vaccines a patient is willing to accept. In Europe, there is variation between countries over what travel vaccines are reimbursed through national healthcare providers. In most cases, travel vaccines will be provided through a mix of public and private care. As per the secondary research findings indicated that although there are a greater annual number of US travelers, European travelers are more likely to visit regions with a high risk of infection.
Components of the report include:
·Overview of Travel-Associated Diseases – Which diseases are vaccinated against in travellers.
·Habits of US and European Travelers – Which travel destinations carry the greatest risk of diseases.
·Travel Vaccine Management – How is the prescription and reimbursement of travel vaccines handled across the US and Europe.
·Established Disease Markets for Travel Vaccines – What are the current and pipeline products available for diseases currently vaccinated against in travellers.
·Emerging Disease Markets for Travel Vaccines – What diseases may be vaccinated against in travellers in the future, and which products are in the pipeline.
·Research and Development Strategies – How are travel vaccine-relevant clinical trials being designed, and what is required for regulatory approval in the US and EU.
Find out more detail at: https://www.marketresearchreports.com/globaldata/travel-vaccines-us-and-european-perspective